Proxygen

Proxygen is a private, preclinical-stage biotech pioneering a systematic approach to discovering molecular glue degraders. Its platform aims to move from serendipitous discovery to orchestrated design of these small molecules, which work by recruiting the cell's natural protein recycling machinery to degrade specific target proteins. The company is building a pipeline targeting proteins across various therapeutic areas and has established key academic collaborations to advance its AI-driven discovery engine. Proxygen is positioned in a high-potential but technically challenging field within targeted protein degradation.

AI-driven platform for the systematic discovery and design of molecular glue degraders, aiming to move from serendipitous finding to orchestrated discovery.

Proxygen competes in the targeted protein degradation (TPD) field, notably against companies developing heterobifunctional degraders (PROTACs) and other molecular glue discoverers like Monte Rosa Therapeutics, Neomorph, and Plexium. Large pharmaceutical companies (e.g., Bristol Myers Squibb, Novartis, Roche) also have significant internal and partnered TPD efforts.